Appendix 4c quarterly activity report for quarter ended march 31, 2024

Fda provides clarity on path to licensure for remestemcel-l in sr-agvhd and rexlemestrocel-l in end-stage heart failure fda provides clarity on path to licensure for remestemcel-l in sr-agvhd and rexlemestrocel-l in end-stage heart failure
MESO Ratings Summary
MESO Quant Ranking